A new study shows accelerated aging is a key risk factor for colon polyps, a precursor to colorectal cancer, and suggests targeted early screening for those aging faster than their chronological age.
Understanding the cellular and molecular factors influencing how NSCLC reacts to neoadjuvant immuno-chemotherapy unlocks more personalized treatments.
The research demonstrates that glioblastoma organoids are a powerful tool for understanding how CAR-T therapy impacts brain tumors.
A new study has identified two distinct subtypes of metabolic dysfunction-associated steatotic liver disease (MASLD). The discovery could lead to improved diagnosis and treatment.
Results from a study presented at the ASH Annual Meeting showed three-year overall survival rates for people in remission with MCL. The study showed those who were treated with rituximab alone versus immunotherapy and a stem cell transplant were very similar.
A study looked at how prevention, screening, and treatment impacted the death rate from colorectal, lung, breast, cervical, and prostate cancer from 1975–2020.
At ASH 2024, the company unveiled Phase I/II safety and efficacy data for BEAM-101 and a preclinical update on their non-genotoxic approach (ESCAPE).
A study, presented at the 2024 ASH annual meeting, details how dietary fiber supports a healthy gut microbiome, which in turn may improve overall survival and reduce complications following bone marrow and stem cell transplants.
Research shows how abnormal microglial cells can contribute to Alzheimer's disease and have identified a possible treatment.
Muna Therapeutics has announced a research alliance with GSK to identify and validate novel drug targets for the treatment of Alzheimer’s disease. The deal will use Muna’s all-in-human MiND-MAP spatial multi-omics platform.
